Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + oxaliplatin + docetaxel + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen of **cadonilimab**, a tetravalent bispecific PD-1/CTLA-4 antibody, plus the chemotherapeutic agents **oxaliplatin** (a platinum-based DNA crosslinker), **docetaxel** (a microtubule inhibitor), and **5-fluorouracil** (a thymidylate synthase inhibitor). Cadonilimab blocks both PD-1 and CTLA-4 pathways, enhancing T cell activation and anti-tumor immune responses with lower immune-related toxicities than combined traditional PD-1 and CTLA-4 monoclonal antibodies[1][2]. The combination with cytotoxic chemotherapy (as seen in various clinical trials and ongoing investigations) is being explored for advanced solid tumors, particularly **gastric/gastroesophageal junction adenocarcinoma**, **cervical cancer**, and **head and neck squamous cell carcinoma**, with reported improved overall response rates and manageable toxicities[2][4][5].
- Other names
- AK104 + oxaliplatin + docetaxel + 5-fluorouracil
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cadonilimab + oxaliplatin + docetaxel + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + oxaliplatin + docetaxel + 5-fluorouracil.